ICOSLG Protein (AA 19-258, C-Term) (Fc Tag)

Catalog No. ABIN2667377

This Recombinant ICOSLG protein is expressed in Escherichia coli (E. coli).

Quick Overview for ICOSLG Protein (AA 19-258, C-Term) (Fc Tag) (ABIN2667377)

Target: ICOSLG (Inducible T-Cell Co-Stimulator Ligand (ICOSLG))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: ELISA, Flow Cytometry (FACS)

Purity: >95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 19-258, C-Term

Purification tag / Conjugate: This ICOSLG protein is labelled with Fc Tag.

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.1 EU per μg of protein as determine by the LAL method

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Immobilized human B7-H2-Fc Chimera at 1 μg/mL (100 μL/well) can bind recombinant human ICOS-Fc in a dose dependent manner with a kD < 5.0 nM.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Concentration: 200 μg/mL

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: ICOSLG (Inducible T-Cell Co-Stimulator Ligand (ICOSLG))

Alternative Name: B7-H2

Background: B7-H2 belongs to the B7 family of immunoregulatory molecules and is a transmembrane glycoprotein of approximately 60 kD. Mature human B7-H2 consists of a 238 amino acid extracellular domain (ECD), two immunoglobulin-like domains, a 21 amino acid transmembrane segment, and a 25 residue cytoplasmic domain. Within the ECD, human B7-H2 shares 50 % and 54 % amino acid sequence identity with mouse and rat B7-H2, respectively. B7-H2 is expressed on antigen presenting cells such as B cells, macrophages, dendritic cells, and also in monocytes. It binds to ICOS and is expressed on activated T cells, which leads to both positive and negative effects on immune responses including its own downregulation. Mouse and human B7-H2 exhibit cross species binding to ICOS. B7-H2 interaction with ICOS is costimulatory for T cell proliferation as well as the development of B cells, plasma cells, follicular helper T cells, and germinal centers. In addition, human B7-H2 binds to CD28 and CTLA4. The interaction of human B7-H2 and CD28 can costimulate both human mouse naive T cells and regulatory T cells (Treg). B7-H2 plays a role in the development of allergic asthma by enhancing Th2 biased immune responses, limiting Th17 responses, and promoting eosinophilic infiltration into the lungs. B7-H2 activation of ICOS on Tregs limits pulmonary inflammation and airway hyper-responsiveness, promotes the development of inhalational tolerance, and impairs anti-tumor immunity.

Molecular Weight: This 478 amino acid recombinant protein with a C-terminal human IgG1 Fc tag has a predicted molecular mass of approximately 54 kDa. The protein migrates as above 55 kDa in SDS-PAGE in DTT-reducing condition and above 110 kDa in non-reducing condition. The

Pathways: Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation